{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:28:53Z","timestamp":1788899333113,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SANOFI-AVENTIS","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Human African Trypanosomiasis (HAT or sleeping sickness) is a life-threatening neglected tropical disease that is endemic in 36 sub-Saharan African countries. Until recently, treatment options were limited and hampered by unsatisfactory efficacy, toxicity, and long and cumbersome administration regimens, compounded by infrastructure inadequacies in the remote rural regions worst affected by the disease. Increased funding and awareness of HAT over the past two decades has led to a steady decline in reported cases (&lt;1000 in 2018). Recent drug development strategies have resulted in development of the first all-oral treatment for HAT, fexinidazole. Fexinidazole received European Medicines Agency positive scientific opinion in 2018 and is now incorporated into the WHO interim guidelines as one of the first-line treatments for HAT, allowing lumbar puncture to become non-systematic. Here, we highlight the role of global collaborations in the effort to control HAT and develop new treatments. The long-standing collaboration between the WHO, Sanofi and the Drugs for Neglected Diseases initiative (Geneva, Switzerland) was instrumental for achieving the control and treatment development goals in HAT, whilst at the same time ensuring that efforts were led by national authorities and control programs to leave a legacy of highly trained healthcare workers and improved research and health infrastructure.<\/jats:p>","DOI":"10.3390\/tropicalmed5010017","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T07:41:11Z","timestamp":1580110871000},"page":"17","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole"],"prefix":"10.3390","volume":"5","author":[{"given":"Philippe","family":"Neau","sequence":"first","affiliation":[{"name":"Sanofi France, 82 avenue Raspail, 94250 Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0862-9642","authenticated-orcid":false,"given":"Heinz","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"Sanofi Deutschland, Industriepark H\u00f6chst, Bldg. H831, 65926 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lameyre","sequence":"additional","affiliation":[{"name":"Sanofi France, 82 avenue Raspail, 94250 Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Strub-Wourgaft","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Kuykens","sequence":"additional","affiliation":[{"name":"Sanofi US, 55 Corporate Drive, Bridgewater, NJ 08807, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"ref_1","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). About Sleeping Sickness. Available online: https:\/\/www.dndi.org\/diseases-projects\/hat\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Franco, J.R., Cecchi, G., Priotto, G., Paone, M., Diarra, A., Grout, L., Simarro, P.P., Zhao, W., and Argaw, D. (2018). Monitoring the elimination of human African trypanosomiasis: Update to 2016. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006890"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-072X-8-15","article-title":"Towards the Atlas of human African trypanosomiasis","volume":"8","author":"Cecchi","year":"2009","journal-title":"Int. J. Health Geogr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"ref_5","unstructured":"World Health Organization (2019, December 17). WHO Interim Guidelines for the Treatment of Gambiense Human African Trypanosomiasis. Available online: https:\/\/www.who.int\/trypanosomiasis_african\/resources\/9789241550567\/en\/."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Checchi, F., Funk, S., Chandramohan, D., Haydon, D.T., and Chappuis, F. (2015). Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. BMC Res. Notes, 8.","DOI":"10.1186\/s13104-015-1244-3"},{"key":"ref_7","unstructured":"WHO (1998). Expert Committee on the Control and Surveillance of African Trypanosomiasis & World Health Organization. Control and Surveillance of African Trypanosomiasis: Report of A WHO Expert Committee, World Health Organization."},{"key":"ref_8","unstructured":"World Health Organization (2019, December 17). Resolutions and decisions, annexes. In Proceedings of the Fiftieth World Health Assembly, Geneva, Switzerland, 5\u201314 May 1997. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/179638."},{"key":"ref_9","unstructured":"World Health Organization (2019, December 17). WHO Programme to Eliminate Sleeping Sickness: Building A Global Alliance 2002. Available online: https:\/\/www.who.int\/trypanosomiasis_african\/resources\/who_cds_csr_eph_2002.13\/en\/."},{"key":"ref_10","unstructured":"World Health Organisation (2019, November 11). WHO HAT Elimination Partners: Donors. Available online: https:\/\/www.who.int\/trypanosomiasis_african\/partners\/partners_donors\/en\/."},{"key":"ref_11","unstructured":"World Health Organisation (2019, November 11). London Declaration on Neglected Tropical Diseases. Available online: https:\/\/www.who.int\/neglected_diseases\/London_Declaration_NTDs.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Franco, J.R., Cecchi, G., Priotto, G., Paone, M., Diarra, A., Grout, L., Mattioli, R.C., and Argaw, D. (2017). Monitoring the elimination of human African trypanosomiasis: Update to 2014. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005585"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Simarro, P.P., Cecchi, G., Franco, J.R., Paone, M., Diarra, A., Ruiz-Postigo, J.A., Fevre, E.M., Mattioli, R.C., and Jannin, J.G. (2012). Estimating and mapping the population at risk of sleeping sickness. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001859"},{"key":"ref_14","unstructured":"SANOFI (2019, November 11). Fighting Negleted Tropical Diseases Factsheet. Available online: https:\/\/www.sanofi.com\/...\/Fighting_Neglected_Tropical_Diseases_2018.pdf."},{"key":"ref_15","unstructured":"World Health Organisation (2019, November 25). Global Health Observatory Data Repository, Human African Trypanosomiasis. Available online: http:\/\/apps.who.int\/gho\/data\/node.main.A1635."},{"key":"ref_16","unstructured":"World Health Organization (2013). Control and Surveillance of Human African Trypanosomiasis: Report of A WHO Expert Committee, World Health Organization."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Barrett, M.P. (2018). The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006925"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(18)30019-9","article-title":"Oral fexinidazole for human African trypanosomiasis","volume":"391","author":"Chappuis","year":"2018","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1752-1505-5-7","article-title":"Challenges of controlling sleeping sickness in areas of violent conflict: Experience in the Democratic Republic of Congo","volume":"5","author":"Tong","year":"2011","journal-title":"Confl. Health"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yun, O., Priotto, G., Tong, J., Flevaud, L., and Chappuis, F. (2010). NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000720"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Gharashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., and Kazadi-Kyanza, S. (2009). Nifurtomox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial. Lancet, 374.","DOI":"10.1016\/S0140-6736(09)61117-X"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_23","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). NECT Dossier. Available online: https:\/\/www.dndi.org\/achievements\/nect\/."},{"key":"ref_24","unstructured":"Sanofi (2019). Summary of Product Characteristics: Fexinidazole Winthrop 600 mg Tablets, Sanofi-Aventis Groupe."},{"key":"ref_25","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). Target Product Profile\u2014Sleeping Sickness. Available online: https:\/\/www.dndi.org\/diseases-projects\/hat\/hat-target-product-profile\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40267-019-00672-2","article-title":"Fexinidazole in human African trypanosomiasis: A profile of its use","volume":"35","author":"Deeks","year":"2019","journal-title":"Drugs Ther. Perspect."},{"key":"ref_29","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). Human African Trypanosomiasis (HAT) Platform. Available online: https:\/\/www.dndi.org\/strengthening-capacity\/hat-platform\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00436-002-0754-9","article-title":"Nitroheterocyclic drugs with broad spectrum activity","volume":"90","author":"Raether","year":"2003","journal-title":"Parasitol. Res."},{"key":"ref_31","unstructured":"Sanofi (2011). Sleeping Sickness: Providing Hope for the Forgotten. Connectome, 2, 5."},{"key":"ref_32","unstructured":"H\u00e4nel, H. Personal Communication."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF00926669","article-title":"The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice","volume":"69","author":"Jennings","year":"1983","journal-title":"Zeitschrift f\u00fcr Parasitenkunde"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00034983.1983.11811668","article-title":"The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica","volume":"77","author":"Raether","year":"1983","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazue, G., Bray, M.A., and Pecoul, B. (2010). Fexinidazole\u2014A new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000923"},{"key":"ref_36","unstructured":"Drugs for Neglected Diseases Initiative (2018). European Medicines Agency Recommends Fexinidazole, the First All-Oral Treatment for Sleeping Sickness, Drugs for Neglected Diseases Initiative. [press release]."},{"key":"ref_37","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). Clinical Trials. Available online: https:\/\/www.dndi.org\/category\/clinical-trials\/."},{"key":"ref_38","unstructured":"(2018). European Medicines Agency Assessment Report: Fexinidazole Winthrop 2018, European Medicines Agency."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"ref_40","unstructured":"Drugs for Neglected Diseases Initiative (2019, November 11). Achievements: Fexinidazole. Available online: https:\/\/www.dndi.org\/achievements\/fexinidazole\/."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pelfrene, E., Harvey Allchurch, M., Ntamabyaliro, N., Nambasa, V., Ventura, F.V., Nagercoil, N., and Cavaleri, M. (2019). The European Medicines Agency\u2019s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007381"},{"key":"ref_42","unstructured":"Drugs for Neglected Diseases Initiative (2019). Fexinidazole, the First All-Oral Treatment for Sleeping Sickness, Approved in Democratic Republic of Congo, Drugs for Neglected Diseases Initiative. [press release]."},{"key":"ref_43","unstructured":"World Health Organization (2019, December 17). WHO Model Lists of Essential Medicines, 21st List 2019. Available online: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"ref_44","unstructured":"Drugs for Neglected Diseases Initiative (2019, December 18). Acoziborole. Available online: https:\/\/www.dndi.org\/diseases-projects\/portfolio\/acoziborole\/."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/17\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:20:41Z","timestamp":1760361641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["tropicalmed5010017"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed5010017","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]}}}